Global Point of Care Molecular Diagnostics Market Overview:
Point of Care Molecular allows a physician to make a diagnosis or rule out a diagnosis and treat a patient while they are still in the clinic. Furthermore, as compared to rapid antigen detection tests, molecular assays have shown better sensitivity, removing the need for secondary confirmation of negative results and leading in much more appropriate antibiotic administration, including the avoidance of antibiotic use for viral infections.
- Microfluidics and Other Instrumentation Technologies That Allow for the Creation of Low-Cost Platforms and Tests
- Time-Consuming and Stringent Government Regulations and Policies
- In Resource-Constrained Environments, Molecular POCT is Becoming Increasingly Beneficial
- Direct Interaction With a Patient During Specimen Collection Poses the Highest Danger
Competitive Landscape and The demand for POC Molecular Diagnostics is increasing by each passing day . The businesses in this industry facing major competition on a global scale with leading players of the market who hold a major market share. The Leading Players are engaging in organic and non-organic strategic global expansion to maintain their Market Position.
Some of the key players profiled in the report are Roche (Switzerland), Abbott Laboratories (United States), Biomerieux (France), Danaher (United States), Roche diagnostics (Switzerland), Meridian biosciences (United States), Quidel (United States), Sanofi (France), Merck (United States) and Johnson and Johnson (United States). Additionally, following companies can also be profiled that are part of our coverage like Cardea (United States), Inflammatix (United States) and Sherlock Biosciences (United States). Analyst at AMA Research see United States Players to retain maximum share of Global Point of Care Molecular Diagnostics market by 2026. Considering Market by Product, the sub-segment i.e. Assays & Kits will boost the Point of Care Molecular Diagnostics market. Considering Market by End-Use, the sub-segment i.e. Physician Offices will boost the Point of Care Molecular Diagnostics market. Considering Market by Tests, the sub-segment i.e. RT-PCR will boost the Point of Care Molecular Diagnostics market.
Latest Market Insights:
In March 2021 Roche Released a Statement Stating the Acquisition of Genmark. The ePlex technology from GenMark provides clinicians with quick and actionable findings, allowing them to pinpoint the source of infection and the most effective therapy, potentially saving lives and reducing healthcare costs. Roche's diagnostic portfolio has been enhanced by the integration of GenMark's unique multiplex technology, which addresses a wide range of infectious disease testing needs, including respiratory and bloodstream infections.
What Can be Explored with the Point of Care Molecular Diagnostics Market Study
Gain Market Understanding
Identify Growth Opportunities
Analyze and Measure the Global Point of Care Molecular Diagnostics Market by Identifying Investment across various Industry Verticals
Understand the Trends that will drive Future Changes in Point of Care Molecular Diagnostics
Understand the Competitive Scenario
- Track Right Markets
- Identify the Right Verticals
The top-down and bottom-up approaches are used to estimate and validate the size of the Global Point of Care Molecular Diagnostics market.
In order to reach an exhaustive list of functional and relevant players various industry classification standards are closely followed such as NAICS, ICB, SIC to penetrate deep in important geographies by players and a thorough validation test is conducted to reach most relevant players for survey in Point of Care Molecular Diagnostics market.
In order to make priority list sorting is done based on revenue generated based on latest reporting with the help of paid databases such as Factiva, Bloomberg etc.
Finally the questionnaire is set and specifically designed to address all the necessities for primary data collection after getting prior appointment by targeting key target audience that includes Venture Capitalists and Private Equity Firms, New Entrants/Investors, Analysts and Strategic Business Planners, Government Regulatory and Research Organizations, Healthcare Organization, Pharmaceutical Companies and End-Use Industries.
This helps us to gather the data related to players revenue, operating cycle and expense, profit along with product or service growth etc.
Almost 70-80% of data is collected through primary medium and further validation is done through various secondary sources that includes Regulators, World Bank, Association, Company Website, SEC filings, OTC BB, USPTO, EPO, Annual reports, press releases etc.
Frequently Asked Questions (FAQ):1. What is the growth rate predicted for the Global Point of Care Molecular Diagnostics Market?
The Point of Care Molecular Diagnostics market is expected to see a CAGR of % during projected year 2020 to 2026.
2. Who are the top performing companies in Point of Care Molecular Diagnostics Market?
Top performing companies in the Global Point of Care Molecular Diagnostics market are Roche (Switzerland), Abbott Laboratories (United States), Biomerieux (France), Danaher (United States), Roche diagnostics (Switzerland), Meridian biosciences (United States), Quidel (United States), Sanofi (France), Merck (United States) and Johnson and Johnson (United States), to name a few.
3. What trending factors would impact Point of Care Molecular Diagnostics Market growth most?
"Rise in CLIA-Waived Molecular POC Tests" is seen as one of major influencing trends for Point of Care Molecular Diagnostics Market during projected period 2020-2026.